AlphAIAlphAI — Financial news for AI agents
investing.comOCT 212 min read$ISRG

Mizuho cuts Intuitive Surgical stock price target on procedure growth slowdown

Mizuho reduced its price target for Intuitive Surgical (ISRG) to $400 from $415, citing a slowdown in procedure growth. ISRG reported Q3 earnings of $3.00 per share on $3.05B revenue, beating estimates. The company lowered its full-year procedure growth guidance to 14-15%. Analysts remain divided, with some upgrading and others lowering targets.

Original reporting
investing.com
Published Oct 21, 2026, 11:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ISRG
Bearish
high confidence
Mentioned
$ISRG
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ISRGBearishHigh
01

Why it matters

The analyst's price target reduction and guidance downgrade may trigger short-term selling pressure.

02

Market read

Primary impact on ISRG stock; secondary effect on robotic surgery sector.

03

What to watch

Potential upside from upcoming product launches and international expansion not fully priced in.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Mizuho's downgrade follows ISRG's Q3 earnings beat but slower-than-expected da Vinci procedure growth.

Company-level read

Ticker impact

$ISRGBearishHigh confidence
Context

Mizuho lowered ISRG's price target to $400 and highlighted slower procedure growth, indicating fresh analyst downgrade.

Expected impact

likely pressure as the market prices in the guidance slowdown and target reduction

Evidence & confidence

The downgrade directly reduces valuation expectations and the guidance slowdown weakens growth outlook.

Market effects

Sector

Robotic surgery peers may face heightened scrutiny on procedure growth rates.

Regional

U.S. healthcare stocks could see modest pullback amid slower adoption signals.

Global

Limited to medical device sector; no broad market effect.

Counterpoint

What could challenge this read

Despite the target cut, ISRG's strong cash flow and market share could support a bounce.

Key entities

  • Company
    Intuitive Surgical

    Medical device maker of da Vinci surgical systems.

  • Analyst
    Mizuho

    Equity research firm issuing the target cut.

Read at source← All news

StoryIntuitive Surgical Q3 2026 earnings beat estimates but shares tumble on $450 M settlement and pricing cuts

Also covered by

3 outlets

Related articles

OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Drops as $450 Million Charge Overshadows Beat

Intuitive Surgical (ISRG) reported Q3 revenue of $3.05B, up 22%, and adjusted earnings of $3.00 per share, beating expectations. However, shares fell due to a $450M antitrust settlement and a cautious growth outlook. GAAP earnings dropped to $1.49 per share, affected by the settlement. The company placed 546 da Vinci systems, with 315 being the newer da Vinci 5 platform.

finance.yahoo.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive’s shares fall 8% after tempering 2026 procedural growth outlook

Intuitive Surgical reported Q3 revenue of $3.01B, up 22% YoY, but shares fell 8% after lowering its 2026 robotic surgery procedure growth outlook to 14-15% from 13.5-15.5%. The company cited US and Chinese market headwinds. Q3 procedures grew 15% YoY, with 546 da Vinci robots placed. CEO Dave Rosa highlighted strong performance across platforms, including FDA clearance for da Vinci 5 in March 2024.

finance.yahoo.com2 min
OCT 21
$ISRGMed

Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported strong Q3 2026 results, with da Vinci system placements up 28% globally. Da Vinci 5 and SP systems accounted for 65% of placements, and the company announced plans for a new manufacturing facility in Malaysia. ISRG also received several regulatory clearances and expects further reimbursement actions for Ion outside the U.S. The company settled a class action lawsuit related to third-party servicing of da Vinci systems.

finance.yahoo.com2 min
OCT 21
$ISRGMedAI 8/10

Stifel reiterates Intuitive Surgical stock rating after Q3 beat

Stifel maintained its Buy rating and $550 target on Intuitive Surgical (ISRG) after Q3 2026 results beat estimates. Revenue grew 20.66% YoY, with procedure growth of 10% in the U.S. and 20% internationally. Analysts have mixed views on the stock, with targets ranging from $400 to $500. Management expects strategic initiatives to boost growth.

investing.com2 min